Mascha Binder

List of Publications by Year
in descending order

86 papers	2,934 citations	257450 24 h-index	206112 48 g-index
89 all docs	89 docs citations	89 times ranked	5666 citing authors

#	Article	IF	Citations
1	Next-Generation Sequencing of T and B Cell Receptor Repertoires from COVID-19 Patients Showed Signatures Associated with Severity of Disease. Immunity, 2020, 53, 442-455.e4.	14.3	281
2	Superantigenic character of an insert unique to SARS-CoV-2 spike supported by skewed TCR repertoire in patients with hyperinflammation. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 25254-25262.	7.1	252
3	Resistance to anti-CD19/CD3 BiTE in acute lymphoblastic leukemia may be mediated by disrupted CD19 membrane trafficking. Blood, 2017, 129, 100-104.	1.4	198
4	The IL-1Î², IL-6, and TNF cytokine triad is associated with post-acute sequelae of COVID-19. Cell Reports Medicine, 2022, 3, 100663.	6.5	175
5	HLA class Iâ€“associated expansion of TRBV11-2 T cells in multisystem inflammatory syndrome in children. Journal of Clinical Investigation, 2021, 131, .	8.2	130
6	High-dose chemotherapy with autologous haemopoietic stem cell transplantation for newly diagnosed primary CNS lymphoma: a prospective, single-arm, phase 2 trial. Lancet Haematology,the, 2016, 3, e388-e397.	4.6	128
7	Clonal expansion and activation of tissue-resident memory-like T _H 17 cells expressing GM-CSF in the lungs of patients with severe COVID-19. Science Immunology, 2021, 6, .	11.9	125
8	Immunophenotyping of Newly Diagnosed and Recurrent Glioblastoma Defines Distinct Immune Exhaustion Profiles in Peripheral and Tumor-infiltrating Lymphocytes. Clinical Cancer Research, 2018, 24, 4187-4200.	7.0	114
9	The autoimmune signature of hyperinflammatory multisystem inflammatory syndrome in children. Journal of Clinical Investigation, 2021, 131, .	8.2	103
10	Monitoring multiple myeloma by next-generation sequencing of V(D)J rearrangements from circulating myeloma cells and cell-free myeloma DNA. Haematologica, 2017, 102, 1105-1111.	3.5	101
11	European Myeloma Network recommendations on tools for the diagnosis and monitoring of multiple myeloma: what to use and when. Haematologica, 2018, 103, 1772-1784.	3.5	86
12	Cetuximab Resistance in Head and Neck Cancer Is Mediated by EGFR-K521 Polymorphism. Cancer Research, 2017, 77, 1188-1199.	0.9	71
13	Liquid biopsy monitoring uncovers acquired RAS-mediated resistance to cetuximab in a substantial proportion of patients with head and neck squamous cell carcinoma. Oncotarget, 2016, 7, 42988-42995.	1.8	64
14	Stereotypical Chronic Lymphocytic Leukemia B-Cell Receptors Recognize Survival Promoting Antigens on Stromal Cells. PLoS ONE, 2010, 5, e15992.	2.5	62
15	Epidermal growth factor receptor mutation mediates cross-resistance to panitumumab and cetuximab in gastrointestinal cancer. Oncotarget, 2015, 6, 12035-12047.	1.8	60
16	Nanobodies effectively modulate the enzymatic activity of CD38 and allow specific imaging of CD38+ tumors in mouse models in vivo. Scientific Reports, 2017, 7, 14289.	3.3	55
17	CLL B-cell receptors can recognize themselves: alternative epitopes and structural clues for autostimulatory mechanisms in CLL. Blood, 2013, 121, 239-241.	1.4	51
18	Differential organization of tonic and chronic B cell antigen receptors in the plasma membrane. Nature Communications, 2019, 10, 820.	12.8	50

#	Article	IF	Citations
19	Long-term CD38 saturation by daratumumab interferes with diagnostic myeloma cell detection. Haematologica, 2017, 102, e368-e370.	3.5	48
20	T cell receptor next-generation sequencing reveals cancer-associated repertoire metrics and reconstitution after chemotherapy in patients with hematological and solid tumors. OncoImmunology, 2019, 8, e1644110.	4.6	44
21	T-cell diversification reflects antigen selection in the blood of patients on immune checkpoint inhibition and may be exploited as liquid biopsy biomarker. International Journal of Cancer, 2017, 140, 2535-2544.	5.1	42
22	Bâ€cell receptor epitope recognition correlates with the clinical course of chronic lymphocytic leukemia. Cancer, 2011, 117, 1891-1900.	4.1	31
23	Local Intracerebral Immunomodulation Using Interleukin-Expressing Mesenchymal Stem Cells in Glioblastoma. Clinical Cancer Research, 2020, 26, 2626-2639.	7.0	31
24	PD-L1 targeting and subclonal immune escape mediated by PD-L1 mutations in metastatic colorectal cancer. , 2021, 9, e002844.		29
25	Nanobody Targeting of Epidermal Growth Factor Receptor (EGFR) Ectodomain Variants Overcomes Resistance to Therapeutic EGFR Antibodies. Molecular Cancer Therapeutics, 2019, 18, 823-833.	4.1	27
26	Denosumab mimics the natural decoy receptor osteoprotegerin by interacting with its major binding site on RANKL. Oncotarget, 2014, 5, 6647-6653.	1.8	27
27	Nextâ€Generation Immunosequencing Reveals Pathological Tâ€Cell Architecture in Autoimmune Hepatitis. Hepatology, 2021, 73, 1436-1448.	7.3	25
28	SARS-CoV-2â€“specific antibody rearrangements in prepandemic immune repertoires of risk cohorts and patients with COVID-19. Journal of Clinical Investigation, 2021, 131, .	8.2	25
29	Maturation trajectories and transcriptional landscape of plasmablasts and autoreactive B cells in COVID-19. IScience, 2021, 24, 103325.	4.1	25
30	Ipilimumab or FOLFOX with Nivolumab and Trastuzumab in previously untreated HER2-positive locally advanced or metastatic EsophagoGastric Adenocarcinoma - the randomized phase 2 INTEGA trial (AIO) Tj ETQq0 0 0 rgBT /Overlock 10 T	2.6	22
31	Detection of SARS-CoV-2 Derived Small RNAs and Changes in Circulating Small RNAs Associated with COVID-19. Viruses, 2021, 13, 1593.	3.3	21
32	Avelumab and cetuximab in combination with FOLFOX in patients with previously untreated metastatic colorectal cancer (MCRC): Results of the safety run-in phase of the phase II AVETUX trial (AIO-KRK-0216).. Journal of Clinical Oncology, 2018, 36, 3561-3561.	1.6	20
33	Bendamustine and rituximab in combination with lenalidomide in patients with chronic lymphocytic leukemia. European Journal of Haematology, 2016, 97, 253-260.	2.2	19
34	Phase III study of nivolumab alone or combined with ipilimumab as immunotherapy versusÂstandard of care in resectable head and neck squamous cell carcinoma. Future Oncology, 2020, 16, 3035-3043.	2.4	18
35	Antigen-specificity of oligoclonal abnormal protein bands in multiple myeloma after allogeneic stem cell transplantation. Cancer Immunology, Immunotherapy, 2012, 61, 1639-1651.	4.2	17
36	The role of B cell antigen receptors in mantle cell lymphoma. Journal of Hematology and Oncology, 2017, 10, 164.	17.0	17

#	Article	IF	Citations
37	High-Throughput Immunogenetics Reveals a Lack of Physiological T Cell Clusters in Patients With Autoimmune Cytopenias. Frontiers in Immunology, 2019, 10, 1897.	4.8	17
38	Nanobody-based CD38-specific heavy chain antibodies induce killing of multiple myeloma and other hematological malignancies. Theranostics, 2020, 10, 2645-2658.	10.0	17
39	Radiosensitization of HNSCC cells by EGFR inhibition depends on the induction of cell cycle arrests. Oncotarget, 2016, 7, 45122-45133.	1.8	17
40	Landscape of Tâ€cell repertoires with public COVIDâ€19â€associated Tâ€cell receptors in preâ€pandemic risk cohorts. Clinical and Translational Immunology, 2021, 10, e1340.	3.8	16
41	Rapid Hypermutation B Cell Trajectory Recruits Previously Primed B Cells Upon Third SARS-Cov-2 mRNA Vaccination. Frontiers in Immunology, 2022, 13, .	4.8	16
42	SLAMF receptors negatively regulate B cell receptor signaling in chronic lymphocytic leukemia via recruitment of prohibitin-2. Leukemia, 2021, 35, 1073-1086.	7.2	15
43	Next-generation sequencing of peripheral B-lineage cells pinpoints the circulating clonotypic cell pool in multiple myeloma. Blood, 2014, 123, 3618-3621.	1.4	14
44	Correlation of nutrition-associated parameters with non-relapse mortality in allogeneic hematopoietic stem cell transplantation. Annals of Hematology, 2022, 101, 681-691.	1.8	12
45	B cells in autoimmune hepatitis: bystanders or central players?. Seminars in Immunopathology, 2022, 44, 411-427.	6.1	12
46	Hospital population screening reveals overrepresentation of CD5â˜' monoclonal B-cell lymphocytosis and monoclonal gammopathy of undetermined significance of IgM type. Annals of Hematology, 2015, 94, 1559-1565.	1.8	11
47	Clinical presentation and diagnosis of adult patients with nonâ€Hodgkin lymphoma in Subâ€Saharan Africa. British Journal of Haematology, 2020, 190, 209-221.	2.5	11
48	Dynamic changes of the normal B lymphocyte repertoire in CLL in response to ibrutinib or FCR chemo-immunotherapy. OncoImmunology, 2018, 7, e1417720.	4.6	10
49	Evolutionary clonal trajectories in nodular lymphocyte-predominant Hodgkin lymphoma with high risk of transformation. Haematologica, 2021, 106, 2654-2666.	3.5	10
50	Analyzing tyrosine kinase activity in head and neck cancer by functional kinomics: Identification of hyperactivated Src family kinases as prognostic markers and potential targets. International Journal of Cancer, 2021, 149, 1166-1180.	5.1	10
51	Azacitidine-induced reconstitution of the bone marrow T cell repertoire is associated with superior survival in AML patients. Blood Cancer Journal, 2022, 12, 19.	6.2	10
52	Complementarity determining region-independent recognition of a superantigen by B-cell antigen receptors of mantle cell lymphoma. Haematologica, 2016, 101, e378-e381.	3.5	9
53	High Aldehyde Dehydrogenase Levels Are Detectable in the Serum of Patients with Lung Cancer and May Be Exploited as Screening Biomarkers. Journal of Oncology, 2019, 2019, 1-11.	1.3	9
54	Severe and irreversible myelopathy after concurrent systemic and intrathecal nucleoside analogue treatment for refractory diffuse large B-cell lymphoma: A case report and review of the literature. Journal of Oncology Pharmacy Practice, 2016, 22, 523-527.	0.9	8

#	Article	IF	Citations
55	A transplant â€œimmunomeâ€•screening platform defines a targetable epitope fingerprint of multiple myeloma. Blood, 2016, 127, 3202-3214.	1.4	7
56	A significant proportion of patients with primary central nervous system lymphoma harbor clonal bone marrow B-cells. Leukemia and Lymphoma, 2019, 60, 334-340.	1.3	7
57	Deep sequencing of bone marrow microenvironments of patients with del(5q) myelodysplastic syndrome reveals imprints of antigenic selection as well as generation of novel T-cell clusters as a response pattern to lenalidomide. Haematologica, 2019, 104, 1355-1364.	3.5	7
58	Early relapse detection by monitoring of circulating cell-free DNA in patients with localized head and neck squamous cell carcinoma: A subgroup analysis of the multicenter randomized clinical trial IMSTAR-HN. Oral Oncology, 2022, 126, 105733.	1.5	7
59	Circulating Tumor DNA in Gastric and Gastroesophageal Junction Cancer. Current Oncology, 2022, 29, 1430-1441.	2.2	7
60	Subclonal heterogeneity sheds light on the transformation trajectory in IGLV3-21R110 chronic lymphocytic leukemia. Blood Cancer Journal, 2022, 12, 49.	6.2	7
61	Drugs targeting integrins for cancer therapy. Expert Opinion on Drug Discovery, 2009, 4, 229-241.	5.0	6
62	Targeting the Mutational Landscape of Bystander Cells: Drug-Promoted Blood Cancer From High-Prevalence Pre-neoplasias in Patients on BRAF Inhibitors. Frontiers in Oncology, 2020, 10, 540030.	2.8	6
63	RBMX Protein Expression in T-Cell Lymphomas Predicts Chemotherapy Response and Prognosis. Cancers, 2021, 13, 4788.	3.7	6
64	Responsiveness to Immune Checkpoint Inhibitors Is Associated With a Peripheral Blood T-Cell Signature in Metastatic Castration-Resistant Prostate Cancer. JCO Precision Oncology, 2020, 4, 1374-1385.	3.0	6
65	Divergent Effects of EZH1 and EZH2 Protein Expression on the Prognosis of Patients with T-Cell Lymphomas. Biomedicines, 2021, 9, 1842.	3.2	6
66	Comment on â€œPrimary Central Nervous System (CNS) Lymphoma B Cell Receptors Recognize CNS Proteinsâ€• Journal of Immunology, 2015, 195, 4549-4550.	0.8	5
67	Overcoming unintended immunogenicity in immunocompetent mouse models of metastasis: the case of GFP. Signal Transduction and Targeted Therapy, 2022, 7, 68.	17.1	5
68	T-cell repertoire profiling by next-generation sequencing reveals tissue migration dynamics of TRBV13-family clonotypes in a common experimental autoimmune encephalomyelitis mouse model. Journal of Neuroimmunology, 2019, 332, 49-56.	2.3	3
69	Homologous recombination repair deficient prostate cancer represents an immunologically distinct subtype. OncoImmunology, 2022, 11, .	4.6	3
70	The phosphotyrosine phosphatase SHP2 promotes anergy in chronic lymphocytic leukemia. Blood, 2018, 131, 1755-1758.	1.4	2
71	Prognostic Impact of Physiological B-Cell Precursors (hematogones) in the Bone Marrow As Determined by Immunophenotyping in the Post-Transplant Period in Patients with AML. Blood, 2012, 120, 1406-1406.	1.4	2
72	Avelumab and cetuximab in combination with FOLFOX in patients with previously untreated metastatic colorectal cancer (MCRC): The phase II AVETUX-CRC trial (AIO KRK 0216).. Journal of Clinical Oncology, 2017, 35, TPS3620-TPS3620.	1.6	2

#	Article	IF	Citations
73	Fulminant blast crisis with de novo 11q23 rearrangement in a Philadelphia-positive CML patient undergoing treatment with dasatinib. Tumori, 2019, 105, NP8-NP11.	1.1	1
74	Impact of bone marrow involvement on outcome in relapsed and refractory transplant eligible diffuse large B-cell lymphoma and transformed indolent lymphoma. PLoS ONE, 2020, 15, e0235786.	2.5	1
75	B-Cell Receptors of Primary Central Nervous System Lymphoma Recognize Antigens in the Brain. Blood, 2014, 124, 3003-3003.	1.4	1
76	Analysis of anti-leukemic activity, predictive biomarker candidates, immune activation and pharmakodynamics in R/R AML and MDS in response to treatment with bemcentinib (BGB324), a first-in class selective AXL inhibitor, in a phase II open-label, multi-centre study.. Journal of Clinical Oncology, 2018, 36, 7020-7020.	1.6	1
77	The immunomodulatory activity of bemcentinib (BGB324): A first-in-class selective oral AXL inhibitor in patients with relapsed/refractory acute myeloid leukemia or myelodysplastic syndrome.. Journal of Clinical Oncology, 2018, 36, 70-70.	1.6	1
78	BGB324 Represents an Axl and BCR-ABL1 Inhibitor with Activity in the T315I Mutant. Blood, 2014, 124, 4512-4512.	1.4	1
79	The role of T-cell phenotype and T-cell receptor rearrangement in the diagnosis of T-cell malignancies: author's reply. Leukemia and Lymphoma, 2015, 56, 3455-3455.	1.3	0
80	IMMU-55. IMMUNOMODULATORY IL-7 AND IL-12-EXPRESSING MSCs INDUCE LONG-TERM SURVIVAL AND IMMUNITY IN SYNGENEIC INTRACEREBRAL GLIOBLASTOMA MODELS. Neuro-Oncology, 2018, 20, vi133-vi134.	1.2	0
81	Cancer Cells Expressing Oncogenic Rat Sarcoma Show Drug-Addiction Toward Epidermal Growth Factor Receptor Antibodies Mediated by Sustained MAPK Signaling. Frontiers in Oncology, 2020, 9, 1559.	2.8	0
82	Evidence for Autostimulatory Mechanisms in Chronic Lymphocytic Leukemia.. Blood, 2012, 120, 2880-2880.	1.4	0
83	Title is missing!. , 2020, 15, e0235786.		0
84	Title is missing!. , 2020, 15, e0235786.		0
85	Title is missing!. , 2020, 15, e0235786.		0
86	Title is missing!. , 2020, 15, e0235786.		0